Miranda

mgreenberg@dcat.org

LATEST

Pfizer, US Gov’t in $5.29-Bn Pact for Oral COVID Drug
By

By
Pfizer has entered into an agreement with the US government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, Paxlovid, in a deal worth up to…

J&J Plans To Separate into Two Standalone Companies
By

By
Johnson & Johnson (J&J) has announced plans to split the company into two separate, standalone publicly traded companies, one focused on pharmaceuticals and medical devices, and the other on consumer…

US Gov’t Seeks More mRNA Vaccine Mfg Production
By

By
The US government is seeking that companies accelerate vaccine manufacturing for COVID-19 and in preparation for future pandemics. The goal of the program is to expand existing capacity by an…

US Gov’t To Buy GSK’s/Vir’s COVID-19 Drug for $1 Bn
By

By
The US government has entered into purchase agreements, totaling approximately $1 billion, with GlaxoSmithKline (GSK) and Vir Biotechnology, a San Francisco-based bio/pharmaceutical company, for sotrovimab, an investigational monoclonal antibody for…

Supplier News: Hovione, Lonza, Arranta Bio & More
By

By
The latest from CDMOs, CMOs, and suppliers featuring Hovione, Lonza, Arranta Bio, Thermo Fisher Scientific, WuXi Advanced Therapies, Stevanato Group, UPS Healthcare, Lykan Bioscience, List Biotherapeutics, and the Center for…

US Gov’t Takes More Action to Address Rx Drug Pricing
By

By
The Biden Administration is taking additional steps to address the cost of prescription drugs by requiring health insurance issuers, employer-based health plans, and other group health plans to report on…

President Biden Nominates New FDA Commissioner
By

By
President Joe Biden announced last week (November 12, 2021) that he plans to nominate Dr. Robert Califf as Commissioner of the US Food and Drug Administration (FDA). His nomination is…

Novo Nordisk To Acquire Dicerna for $3.3 Bn
By

By
Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals, a Lexington, Massachusetts-based bio/pharmaceutical company specializing in ribonucleic acid interference (RNAi) therapeutics, for $3.3 billion. Using its proprietary RNAi technologies, Dicerna develops…

Pfizer Completes $2.22-Bn Acquisition of Trillium
By

By
Pfizer has completed its acquisition of Trillium Therapeutics, a Mississauga, Ontario, Canada-based clinical-stage immuno-oncology company, for an aggregate purchase price of approximately $2.22 billion. Trillium’s two lead molecules, TTI-622 and…

Gilead, Arcus in $725-M Acquisition, Research Pact
By

By
Gilead Sciences has exercised options to acquire three clinical-stage programs from Arcus Biosciences, a Hayward, California bio/pharmaceutical company focused on cancer immunotherapies, for $725 million. The companies also entered into…